Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 39 Brain Neoplasms 17 Astrocytoma 16 Central Nervous System Neoplasms 9 Oligodendroglioma 8 Gliosarcoma 8 Melanoma 7 Glioma 7 Neoplasms 5 Recurrence 4 Neoplasm Metastasis 3 Neuroblastoma 2 Ganglioneuroblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Choroid Plexus Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Sarcoma, Ewing 1 Sarcoma 1 Rhabdoid Tumor 1 Rare Diseases 1 Optic Nerve Glioma 1 Neurotoxicity Syndromes 1 Neuroendocrine Tumors 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms, Neuroepithelial 1 Neoplasms, Connective and Soft Tissue 1 Neoplasms, Connective Tissue 1 Neoplasms, Bone Tissue 1 Neoplasms by Histologic Type 1 Melanoma, Cutaneous Malignant 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡